Literature DB >> 23723490

Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis.

Sankha Koley1, Rajesh Kumar Mandal, Sanjiv Choudhary, Arghya Bandyopadhyay.   

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is an unusual dermatosis occurring following an attack of visceral leishmaniasis (VL). There are only few reports of PKDL after successful treatment with miltefosine. We report two cases of PKDL that developed after successful treatment of VL with miltefosine.

Entities:  

Keywords:  Miltefosine; post-kala-azar dermal leishmaniasis; visceral leishmaniasis

Year:  2013        PMID： 23723490      PMCID： PMC3667302          DOI： 10.4103/0019-5154.110848

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN： 0019-5154            Impact factor:   1.494


  9 in total

1.  Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases.

Authors:  M C Sharma; A K Gupta; N Verma; V N Das; R Saran; S K Kar
Journal:  J Commun Dis       Date:  2000-03

2.  Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India.

Authors:  Kamlesh Gidwani; Albert Picado; Bart Ostyn; Shri Prakash Singh; Rajiv Kumar; Basudha Khanal; Veerle Lejon; François Chappuis; Marleen Boelaert; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

3.  Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.

Authors:  D Kumar; V Ramesh; S Verma; M Ramam; P Salotra
Journal:  Ann Trop Med Parasitol       Date:  2009-12

4.  Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.

Authors:  V Ramesh; G K Katara; S Verma; P Salotra
Journal:  Br J Dermatol       Date:  2011-08       Impact factor: 9.302

5.  Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen.

Authors:  Sarman Singh; Veena Kumari; Niti Singh
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

6.  Oral miltefosine for Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; C P Thakur; Juergen Engel; Herbert Sindermann; Christina Fischer; Klaus Junge; Anthony Bryceson; Jonathan Berman
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

7.  rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection.

Authors:  E E Zijlstra; N S Daifalla; P A Kager; E A Khalil; A M El-Hassan; S G Reed; H W Ghalib
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

8.  Post-kala-azar dermal leishmaniasis: a histopathological study.

Authors:  Sanjay K Rathi; R K Pandhi; P Chopra; N Khanna
Journal:  Indian J Dermatol Venereol Leprol       Date:  2005 Jul-Aug       Impact factor: 2.545

9.  Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Authors:  Vidya Nand Rabi Das; Krishna Pandey; Neena Verma; Chandra Shekhar Lal; Sanjeev Bimal; Roshan Kamal Topno; Dharmendra Singh; Niyamat Ali Siddiqui; Rakesh Bihari Verma; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2009-03       Impact factor: 2.345
  9 in total
  4 in total

1.  Post-kala-Azar dermal leishmaniasis: A diagnostic dilemma in a nonendemic area.

Authors:  Prachi Bhandare; Pankaj Shukla; Mayur Bhobe; Varadraj V Pai
Journal:  Indian Dermatol Online J       Date:  2014-12

Review 2.  The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Authors:  Eduard E Zijlstra
Journal:  Parasit Vectors       Date:  2016-08-23       Impact factor: 3.876

3.  Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.

Authors:  Dinesh Mondal; Amresh Kumar; Abhijit Sharma; Moshtaq Mural Ahmed; Md Golam Hasnain; Abdul Alim; M Mamun Huda; Ridwanur Rahman; Jorge Alvar; Be-Nazir Ahmed; Rashidul Haque
Journal:  PLoS Negl Trop Dis       Date:  2019-08-15

4.  Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (FungisomeTM) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy.

Authors:  Rama Prosad Goswami; Mehebubar Rahman; Sukhen Das; Santanu Kumar Tripathi; Rudra Prosad Goswami
Journal:  Am J Trop Med Hyg       Date:  2020-05-07       Impact factor: 2.345
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.